Related Experiment Videos
Selective estrogen receptor modulation: concept and consequences in cancer
1Northwestern University, Chicago, IL, USA. vcjordan@northwestern.edu
Cancer Cell
|March 31, 2004
Summary
Extended antihormonal therapy for breast cancer leads to drug resistance, but also a paradoxical estrogen supersensitivity that can induce cancer cell death, offering new therapeutic avenues.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Selective estrogen receptor modulators (SERMs) and aromatase inhibitors are standard treatments for breast cancer and osteoporosis.
- Extended use of these antihormonal therapies can lead to drug resistance and treatment failure.
Purpose of the Study:
- To investigate the consequences of exhaustive antihormonal therapy in breast cancer.
- To explore novel therapeutic strategies based on observed drug resistance mechanisms.
Main Methods:
- Review of established therapeutic strategies involving SERMs and aromatase inhibitors.
- Analysis of the effects of drug resistance on cancer cell survival and apoptosis.
Main Results:
- Drug resistance to SERMs and aromatase inhibitors paradoxically enhances cancer cell survival.
- A subsequent supersensitivity to estrogen action develops, leading to cancer cell apoptosis.
Conclusions:
- Understanding the dual effects of antihormonal therapy resistance is crucial for future breast cancer treatment.
- Exploiting the paradoxical estrogen supersensitivity could enable selective cancer cell killing with reduced patient side effects.